|
1
|
Bowcock AM and Kreuger JG: Getting under
the skin: The immunogenetics of psoriasis. Nat Rev Immunol.
5:699–711. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lynde CW, Poulin Y, Vender R, Bourcier M
and Khalil S: Interleukin 17A: Toward a new understanding of
psoriasis pathogenesis. J Am Acad Dermatol. 71:141–150. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Raychaudhuri SP: Role of IL-17 in
psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol.
44:183–193. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakajima K: Critical role of the
interleukin-23/T-helper 17 cell axis in the pathogenesis of
psoriasis. J Dermatol. 39:219–224. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nerlov C: The C/EBP family of
transcription factors: A paradigm for interaction between gene
expression and proliferation control. Trends Cell Biol. 17:318–324.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Roe JS and Vakoc CR: C/EBPα: Critical at
the origin of leukemic transformation. J Exp Med. 211:1–4. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zaragoza K, Bégay V, Schuetz A, Heinemann
U and Leutz A: Repression of transcriptional activity of C/EBPalpha
by E2F-dimerization partner complexes. Mol Cell Biol. 30:2293–2304.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Johnson PF: Molecular stop signs: R
egulation of cell-cycle arrest by C/EBP transcription factors. J
Cell Sci. 118:2545–2555. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oh WJ, Rishi V, Orosz A, Gerdes MJ and
Vinson C: Inhibition of CCAAT/enhancer binding protein family DNA
binding in mouse epidermis prevents and regresses papillomas.
Cancer Res. 67:1867–1876. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Leonardi C, Matheson R, Zachariae C,
Cameron G, Li L, Edson-Heredia E, Braun D and Banerjee S:
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic
plaque psoriasis. N Engl J Med. 366:1190–1199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kagami S, Rizzo HL, Lee JJ, Koguchi Y and
Blauvelt A: Circulating Th17, Th22, and Th1 cells are increased in
psoriasis. J Invest Dermatol. 130:1373–1383. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reich K: Anti-interleukin-17 monoclonal
antibody ixekizumab in psoriasis. N Engl J Med. 367:274–275. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Papp KA, Leonardi C, Menter A, Ortonne JP,
Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH and
Baumgartner S: Brodalumab, an anti-interleukin-17-receptor antibody
for psoriasis. N Engl J Med. 366:1181–1189. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim HR, Cho ML, Kim KW, Juhn JY, Hwang SY,
Yoon CH, Park SH, Lee SH and Kim HY: Up-regulation of IL-23p19
expression in rheumatoid arthritis synovial fibroblasts by IL-17
through PI3-kinase-, NF-kappaB-and p38 MAPK-dependent signalling
pathways. Rheumatology (Oxford). 46:57–64. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gu C, Wu L and Li X: IL-17 family,
Cytokines, receptors and signaling. Cytokine. 64:477–485. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Papp KA, Reid C, Foley P, Sinclair R,
Salinger DH, Williams G, Dong H, Krueger JG, Russell CB and Martin
DA: Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical
response in subjects with moderate to severe psoriasis, Results
from a phase I, randomized, placebo-controlled trial. J Invest
Dermatol. 132:2466–2469. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ramji D and Foka P: CCAAT/enhancer-binding
proteins: Structure function and regulation. Biochem J.
365:561–575. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tada Y, Brena RM, Hackanson B, Morrison C,
Otterson GA and Plass C: Epigenetic modulation of tumor suppressor
CCAAT/enhancer binding protein alpha activity in lung cancer. J
Natl Cancer Inst. 98:396–406. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Seifeddine R, Dreiem A, Blanc E,
Fulchignoni-Lataud MC, Le Frère Belda MA, Lecuru F, Mayi TH, Mazure
N, Favaudon V, Massaad C, et al: Hypoxia down-regulates
CCAAT/enhancer binding protein-alpha expression in breast cancer
cells. Cancer Res. 68:2158–2165. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tseng HH, Hwang YH, Yeh KT, Chang JG, Chen
YL and Yu HS: Reduced expression of C/EBP alpha protein in
hepatocellular carcinoma is associated with advanced tumor stage
and shortened patient survival. J Cancer Res Clin Oncol.
135:241–247. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shim M, Powers KL, Ewing SJ, Zhu S and
Smart RC: Diminished expression of C/EBPalpha in skin carcinomas is
linked to oncogenic Ras and reexpression of C/EBPalpha in carcinoma
cells inhibits proliferation. Cancer Res. 65:861–867.
2005.PubMed/NCBI
|
|
22
|
Reckzeh K and Cammenga J: Molecular
mechanisms underlying deregulation of C/EBPalpha in acute myeloid
leukemia. Int J Hematol. 91:557–568. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Harris TE, Albrecht JH, Nakanishi M and
Darlington GJ: CCAAT/enhancer-binding protein-alpha cooperates with
p21 to inhibit cyclin-dependent kinase-2 activity and induces
growth arrest independent of DNA binding. J Biol Chem.
276:29200–29209. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang GL, Shi X, Salisbury E, Sun Y,
Albrecht JH and Smith RG: andT imchenko NA: Cyclin D3 maintains
growth-inhibitory activity of C/EBPalpha by stabilizing
C/EBPalpha-cdk2 and C/EBPalpha-Brm complexes. Mol Cell Biol.
26:2570–2582. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rishi L, Hannon M, Salomè M, Hasemann M,
Frank AK, Campos J, Timoney J, O'Connor C, Cahill MR, Porse B and
Keeshan K: Regulation of Trib2 by an E2F1-C/EBPα feedback loop in
AML cell proliferation. Blood. 123:2389–2400. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Datta J, Majumder S, Kutay H, Motiwala T,
Frankel W, Costa R, Cha HC, MacDougald OA, Jacob ST and Ghoshal K:
Metallothionein expression is suppressed in primary human
hepatocellular carcinomas and is mediated through inactivation of
CCAAT/enhancer binding protein alpha by phosphatidylinositol
3-kinase signaling cascade. Cancer Res. 67:2736–2746. 2007.
View Article : Google Scholar : PubMed/NCBI
|
